...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin
【24h】

Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin

机译:应用免疫调节剂IL-2,BCG和褪黑激素后对不可治愈的肝细胞癌的治疗反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aim: Application of immunotherapy to a patient with untreatable hepatocellular carcinoma. Case Report: The patient had a tumor of 60 mm in the liver. The pathological anatomic diagnosis was adenoma. However, after surgery of the tumor seven new lesions arose, showing that the original tumor had been a hepatocellular carcinoma. In addition, when hepatocellular adenomas grow to a size of more than 6-8 cm, they are considered cancerous and thus become a risk for hepatocellular carcinoma. The patient was treated with interleukin-2, Bacillus Calmette Guerin, and melatonin. Results: During treatment, the alpha-fetoprotein levels in blood fell from 5,000 IU/ml to zero, at which level it remained during the followup period of two years. No tumor was detectable on MRI and CT. Six years after the diagnosis of untreatable hepatocellular carcinoma, the patient remains in a good condition. Conclusion: In this case, combined immunomodulating therapy was effective. For patients with metastasized tumors of the liver who are not suitable for conventional therapy, immunomodulation may delay tumor progression, induce tumor regression, or even be curative in some patients. Immunotherapeutic approaches combined with conventional methods for hepatocellular carcinoma treatment may be able to improve therapeutic efficacy.
机译:目的:将免疫疗法应用于无法治愈的肝细胞癌患者。病例报告:该患者的肝脏肿瘤为60毫米。病理解剖诊断为腺瘤。然而,在对肿瘤进行手术后,出现了七个新的病变,表明原始肿瘤是肝细胞癌。此外,当肝细胞腺瘤长到6-8厘米以上时,就被认为是癌性的,因此有患肝细胞癌的风险。该患者接受了白细胞介素2,卡介苗芽孢杆菌和褪黑激素的治疗​​。结果:在治疗期间,血液中的甲胎蛋白水平从5,000 IU / ml降至零,并在两年的随访期内保持在该水平。 MRI和CT均未检测到肿瘤。在诊断为不可治愈的肝细胞癌六年后,患者仍处于良好状态。结论:在这种情况下,联合免疫调节疗法是有效的。对于不适合常规治疗的患有转移性肝肿瘤的患者,免疫调节可能会延迟肿瘤进展,诱导肿瘤消退,甚至在某些患者中可以治愈。免疫治疗方法与常规方法联合用于肝细胞癌治疗可能能够提高治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号